reports
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Mathijs Geerts Danau
Sequana Medical New DSR patent improves value of program
Sequana announces granting of a key additional methods and formulation patent for DSR. This patent increases durability and expands protection of Sequana's DSR IP, thereby improving its value. We note that the patent provides additional time for Sequana to secure dedicated financing to advance DSR toward the randomized controlled portion of the MOJAVE clinical study. We reiterate our BUY rating.
- ING Helpdesk
Benelux Morning Notes
Colruyt: Guidance reiterated despite weaker-than-expected 1H25/26. Dutch Pension Buyouts: Regulator DNB's view, c.€7bn so far, insurers at 15% market share now. OCI: Dutch investor association VEB and other shareholders take legal action to block Orascom merger. Proximus: CFO Mark Reid to leave Proximus by end of January 2026. Staffing Sector: US temp volume YoY declined vs October; NFP jobs beat expectations. Var Energy: Boosting production bodes well for years to come. Events Calendar
Koninklijke Ahold Delhaize N.V.: 1 director
A director at Koninklijke Ahold Delhaize N.V. sold 58,000 shares at 34.380EUR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Thomas Couvreur
ABN Amro NIBC, Wealth & Staff reductions drive value; target price inc...
We have reviewed our model on ABN Amro, incorporating the NIBC acquisition, the ambitious growth targets in Wealth Management and the aggressive cost savings targets, mainly driven by FTE reductions. By FY28 we see our income estimates increase by 4.3% and cost estimates decrease by 3.1%. Our new SoTP valuation points to a target price of €29 (vs €25.5), reiterating our Hold recommendation given limited upside.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
ABN AMRO announces significant risk transfer transaction with Blacksto...
ABN AMRO announces significant risk transfer transaction with Blackstone ABN AMRO announces significant risk transfer transaction with Blackstone 11 December 2025 Today, ABN AMRO announces a significant risk transfer (SRT) transaction with funds manged by Blackstone. This transaction provides first loss protection on a EUR 2 billion portfolio of large corporate loans. The transaction underscores our commitment to creating more room for further profitable growth by actively managing portfolios. We expect the transaction will reduce the bank's risk-weighted assets by EUR 1.6 billion, while...
ABN AMRO kondigt significante risico-overdrachtstransactie aan met Bla...
ABN AMRO kondigt significante risico-overdrachtstransactie aan met Blackstone ABN AMRO kondigt significante risico-overdrachtstransactie aan met Blackstone 11 december 2025 Vandaag kondigt ABN AMRO een significante risico-overdrachtstransactie (SRT) aan met fondsen beheerd door Blackstone. Deze transactie biedt bescherming tegen eerste verliezen op een portefeuille van EUR 2 miljard aan leningen aan grote bedrijven. De transactie onderstreept onze toewijding om actief onze portefeuilles te beheren en meer ruimte te creëren voor verdere winstgevende groei. We verwachten dat de transactie ...
- ING Helpdesk
ABN Amro Bank N.V.: 1 director
A director at ABN Amro Bank N.V. bought 5,350 shares at 29.160EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Marine Leleux
- Maureen Schuller
- Suvi Platerink Kosonen
- Marine Leleux
- Maureen Schuller
- Suvi Platerink Kosonen
Bank Brunch/ABN AMRO new targets
ABN AMRO (ABNANV) outlined new financial targets for 2028 this morning. One of the main angles is the cost base and the substantial expected headcount reductions, following the integration of HAL and eventually NIBC. Regarding capital the new targets would entail at least 235bp headroom to MDA trigger levels. We consider the cost targets as ambitious and that they should support efficiency metrics going forward. That being said, reaching the return on equity target could come eventually with a l...
- ING Helpdesk
Benelux Morning Notes
ABN AMRO: CMD targets at higher end, bold FTE cut to clinch 55% C/I ratio, lower CoRisk. D'Ieteren: Key Belron US glass supplier Fuyao connected to US labour allegations. Elia: Preview 3Q25 update; fine-tuning guidance to upper end of range?. NSI: KPN to leave Glass House, c.7.5% additional vacancy. SBM Offshore: Another step towards SEAP 1+2 FPSO awards. Universal Music Group: Spotify to increase its US subscription prices in 1Q26
- Jacob Mekhael
- Lynn Hautekeete
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
ABN AMRO to sell Alfam to Rabobank
ABN AMRO to sell Alfam to Rabobank ABN AMRO to sell Alfam to RabobankPersonal loans offered via a third-party arrangement25 November 2025Today, ABN AMRO announces that it has reached an agreement on the sale of its fully-owned subsidiary Alfam, ABN AMRO’s personal loan business, to Rabobank. ABN AMRO will continue to offer personal loans to its clients, now via a third-party arrangement with Rabobank.The personal loans market is highly competitive, making scale increasingly important. By joining forces with Rabobank, a well-regarded and reliable partner, clients will continue to receive hig...
ABN AMRO verkoopt Alfam aan Rabobank
ABN AMRO verkoopt Alfam aan Rabobank ABN AMRO verkoopt Alfam aan RabobankPersoonlijke leningen aangeboden via een ‘third-party arrangement’25 november 2025 ABN AMRO maakt vandaag bekend dat zij overeenstemming heeft bereikt over de verkoop van haar volledige dochteronderneming Alfam aan Rabobank. Alfam is het onderdeel van ABN AMRO dat persoonlijke leningen verstrekt. ABN AMRO blijft persoonlijke leningen aanbieden aan haar klanten, nu via een zogenoemde ‘third-party arrangement’ met Rabobank. De concurrentie op de markt voor persoonlijke leningen is zeer groot en schaalgrootte wordt daard...
ABN AMRO presents roadmap for profitable growth and new financial targ...
ABN AMRO presents roadmap for profitable growth and new financial targets for 2028 ABN AMRO presents roadmap for profitable growth and new financial targets for 2028 25 November 2025 Today, ABN AMRO presents the bank’s new strategy and financial outlook for 2026-2028 at its Capital Markets Day. The new plan is designed to deliver profitable growth and enhanced value for all stakeholders. There are three strategic priorities for the coming years: accelerating profitable growth, right-sizing the bank’s cost base, including a net reduction of the workforce by 5,200 FTEs by 2028 compared...
ABN AMRO presenteert strategie voor winstgroei en nieuwe financiële do...
ABN AMRO presenteert strategie voor winstgroei en nieuwe financiële doelen voor 2028 ABN AMRO presenteert strategie voor winstgroei en nieuwe financiële doelen voor 2028 25 november 2025 Vandaag presenteert ABN AMRO tijdens de Capital Markets Day haar nieuwe strategie en financiële vooruitzichten voor 2026 - 2028. Het nieuwe plan richt zich op winstgroei en het vergroten van de waarde voor alle stakeholders. Voor de komende jaren heeft de bank drie strategische prioriteiten geformuleerd: het versnellen van winstgevende groei, het optimaliseren van de kostenbasis van de bank, onder ander...
- Jacob Mekhael
Onward Medical Uneventful 3Q25 results, pivotal Empower BP trial to st...
Onward reported its 3Q25 results, which show no major surprises as the company previously announced the sale of 40 devices in the US in a preliminary update. With a cash position of € 77.7m, Onward is funded into 1Q27 assuming no drawdown of its debt facility. In the pipeline, timelines were reiterated and the company continues to expect to initiate the pivotal Empower BP trial of the ARC-IM system in blood pressure instability by YE25, which means interim results could come in 2H26. We reiterat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.